Communiqués ULTS ASA

Actions

ULTI

NO0010851603

Temps réel Oslo Bors 10:21:18 18/09/2026			Varia. 5j.	Varia. 1 janv.
20,30 ^NOK	-0,49%		-3,77%	+831,19%

03/03/25	Ultimovacs ASA a changé son symbole boursier de ULTI à ZLNA.	CI
03/03/25	Zelluna Immunotherapy AS a acquis Ultimovacs ASA dans le cadre d'une opération de fusion inversée.	CI

Communiqués

09/09	ULTS : List of Representatives 09.09.2026	PU
17/08	Zelluna ASA: Notice of EGM - experienced international biotech executive proposed for election to the Board and Board member steps down	AQ
17/08	Zelluna ASA: Notice of EGM – experienced international biotech executive proposed for election to the Board and Board member steps down	PU
17/08	Zelluna ASA: Notice of EGM - experienced international biotech executive proposed for election to the Board and Board member steps down	PU
19/05	ULTS : Poster presented at ASGCT (19.05.2026)	PU
07/05	ULTS : Q1 2026 report and presentation (Presentation)	PU
07/05	ULTS : Q1 2026 report and presentation (Report)	PU
24/04	Zelluna ASA - Annual General Meeting held on April 23, 2026	AQ
16/04	ULTS : Capital Marked Update (14.04.2026)	PU
14/04	ULTS : Capital Marked Update (14 April 2026)	PU
26/03	ULTS : Appendix 3 Remuneration Guidelines 2026	PU
26/03	ULTS : Appendix 4 Remuneration Report 2025	PU
26/03	ULTS : Appendix 5 Recommendations by the Nomination Committee 2025	PU
25/03	ULTS : ESG Report 2025	PU
25/03	ULTS : Annual Report 2025 and European Single Electronic Format (ESEF) zip file (Report)	PU
17/03	ULTS : Zelluna Publishes Compelling Preclinical Data for ZI-MA4-1, the World's First MAGE-A4-Targeting TCR-NK Therapy for Solid Tumours	PU
17/03	ULTS : Zelluna Reaches Major Milestone and Submits Clinical Trial Application in the UK for First-in-Human Study of ZI-MA4-1 (ZIMA-101), the World’s First MAGE-A4-Targeting TCR-NK Cell Therapy for Solid Tumours	PU
17/03	Zelluna ASA: Approval and publication of prospectus	PU
17/03	ULTS : Zelluna promotes Emilie Gauthy to Chief Technology Officer	PU
17/03	ULTS : Zelluna ASA – Grant of Share Options	PU
17/03	ULTS : Zelluna selects Medpace as CRO for ZIMA-101 first-in-human clinical trial	PU
17/03	Zelluna ASA: Fourth Quarter 2025 – Key regulatory milestone achieved with CTA Submission	PU
17/03	ULTS : Zelluna Receives UK MHRA and Ethics Approval to Initiate ZIMA-101 First-in-Human Clinical Trial	PU
12/02	ULTS : Q4 2025 report and presentation (Report)	PU
12/02	ULTS : Q4 2025 report and presentation (Presentation)	PU